FDA approves groundbreaking pancreatic cancer pill that doubles survival
TL;DR Summary
The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque), a daily pill that nearly doubles median survival in pancreatic cancer in a trial of about 500 patients versus chemotherapy, signaling a major advance in treating one of the deadliest cancers.
- FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives The Washington Post
- F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer The New York Times
- FDA approves landmark pancreatic cancer drug that’s shown to improve survival The Boston Globe
- FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ
- U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease Scientific American
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
20 min
vs 21 min read
Condensed
99%
4,051 → 39 words
Want the full story? Read the original article
Read on The Washington Post